Abstract

Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2

Author(s): Giacoia George P, Taylor-Zapata Perdita, Mattison Donald

Issue: May/Jun 2007 - Pain Management

Page(s): 220-225

Download in electronic PDF format for $75
  • Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Page 1
  • Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Page 2
  • Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Page 3
  • Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Page 4
  • Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Page 5
  • Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Page 6

Abstract

The development and compounding of pharmacotherapeutic formulations that are suitable for infants and young children can be a challenging problem. This problem results from the lack of knowledge on the acceptability of different dosage forms and formulations to children in relation to age and developmental status, as well as the lack of reliable documentation of formulations used in pediatric clinical trials. As part of its mandate under the Best Pharmaceuticals for Children Act to improve pediatric therapeutics, the National Institute of Child Health and Human Development has sponsored the Pediatric Formulations Initiative. The goal of this ongoing initiative is to address the issues and concerns associated with pediatric therapeutics by convening groups of researchers and experts in pediatric formulations from academia, pharmaceutical companies, the National Institutes of Health, and the U.S. Food and Drug Administration. In this second part of a two-part article, the activities of the various groups that c

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2007
Pg. 220-225
Jan/Feb 2007
Pg. 5-8
Jan/Feb 2001
Pg. 6-8
Author(s): Preckshot John
Nov/Dec 2022
Pg. 516-521
Jan/Feb 2001
Pg. 9-12
Author(s): Schotik Debora
Sep/Oct 2006
Pg. 390
Author(s): Allen Loyd V Jr
Nov/Dec 2005
Pg. 410
Author(s): Allen Loyd V Jr
Nov/Dec 2005
Pg. 456-461
Author(s): Fonseca Simonne C
Jul/Aug 1999
Pg. 274-276
Author(s): Nahata Milap C
Jan/Feb 2007
Pg. 17-19
Jan/Feb 2009
Pg. 6-12
May/Jun 2016
Pg. 257-261
Jul/Aug 2008
Pg. 365-367
Jan/Feb 2004
Pg. 10-14
Author(s): Preckshot John
May/Jun 2016
Pg. 247-249
Author(s): Nahata Milap C
Mar/Apr 1997
Pg. 84-86
Author(s): Allen Loyd V Jr
Jan/Feb 2009
Pg. 14-18
Jan/Feb 2011
Pg. 32-40
Author(s): Newton David W
Sep/Oct 2010
Pg. 401-405
Mar/Apr 2012
Pg. 104-109